KalVista Pharmaceuticals (KALV) Insider Trading & Ownership $10.69 +0.12 (+1.14%) (As of 09/18/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KalVista Pharmaceuticals (NASDAQ:KALV) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage12.30%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$5.81 MNumber OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$2.76 M Get KALV Insider Trade Alerts Want to know when executives and insiders are buying or selling KalVista Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address KALV Insider Buying and Selling by Quarter Ad Paradigm PressKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election Meltdown” coming this November.Click here now to see Jim’s shocking predictions for November. KalVista Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/9/2024Benjamin L PalleikoCEOSell7,352$12.19$89,620.88 8/23/2024Paul K AudhyaInsiderSell2,135$12.40$26,474.00 8/19/2024Benjamin L PalleikoCEOSell14,215$12.01$170,722.15 8/19/2024Christopher YeaInsiderSell7,102$12.01$85,295.02 6/7/2024Benjamin L PalleikoCEOSell7,465$11.53$86,071.45 5/20/2024Benjamin L PalleikoCEOSell21,959$11.76$258,237.84 China Stockpiling Gold “Like No Tomorrow” (Ad)For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide.5/20/2024Edward P FeenerInsiderSell8,088$11.76$95,114.88 2/20/2024Benjamin L PalleikoCFOSell22,802$14.11$321,736.22 2/20/2024Edward P FeenerInsiderSell28,288$14.07$398,012.16 2/20/2024Thomas Andrew CrockettCEOSell24,888$14.11$351,169.68 2/8/2024Venrock Healthcare Capital ParMajor ShareholderBuy29,747$14.70$437,280.90 2/6/2024Venrock Healthcare Capital ParMajor ShareholderBuy4,474$14.74$65,946.76 1/29/2024Venrock Healthcare Capital ParMajor ShareholderBuy80,600$14.22$1,146,132.00 1/26/2024Venrock Healthcare Capital ParMajor ShareholderBuy4,174$12.98$54,178.52 1/24/2024Venrock Healthcare Capital ParMajor ShareholderBuy20,686$12.44$257,333.84 1/22/2024Venrock Healthcare Capital ParMajor ShareholderBuy67,546$12.55$847,702.30 1/18/2024Venrock Healthcare Capital ParMajor ShareholderBuy39,680$12.51$496,396.80 1/16/2024Venrock Healthcare Capital ParMajor ShareholderBuy19,599$12.73$249,495.27 1/11/2024Edward P FeenerInsiderSell22,679$13.03$295,507.37 1/10/2024Venrock Healthcare Capital ParMajor ShareholderBuy47,700$12.67$604,359.00 1/8/2024Edward P FeenerInsiderSell17,221$13.01$224,045.21 1/8/2024Venrock Healthcare Capital ParMajor ShareholderBuy69,184$12.44$860,648.96 1/3/2024Venrock Healthcare Capital ParMajor ShareholderBuy17,605$12.20$214,781.00 12/29/2023Venrock Healthcare Capital ParMajor ShareholderBuy6,013$12.49$75,102.37 12/27/2023Thomas Andrew CrockettCEOSell30,000$12.02$360,600.00 12/27/2023Venrock Healthcare Capital ParMajor ShareholderBuy41,514$11.97$496,922.58 (Data available from 1/1/2013 forward) KALV Insider Trading Activity - Frequently Asked Questions Who is on KalVista Pharmaceuticals's Insider Roster? The list of insiders at KalVista Pharmaceuticals includes Albert Cha, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Paul K Audhya, Thomas Andrew Crockett, and Venrock Healthcare Capital Par. Learn more on insiders at KALV. What percentage of KalVista Pharmaceuticals stock is owned by insiders? 12.30% of KalVista Pharmaceuticals stock is owned by insiders. Learn more on KALV's insider holdings. Which KalVista Pharmaceuticals insiders have been buying company stock? The following insider purchased KALV shares in the last 24 months: Venrock Healthcare Capital Par ($5,806,280.30). How much insider buying is happening at KalVista Pharmaceuticals? Insiders have purchased a total of 448,522 KALV shares in the last 24 months for a total of $5,806,280.30 bought. Which KalVista Pharmaceuticals insiders have been selling company stock? The following insiders have sold KALV shares in the last 24 months: Albert Cha ($189,000.00), Benjamin L Palleiko ($1,149,407.95), Christopher Yea ($117,895.74), Edward P Feener ($1,012,679.62), Paul K Audhya ($138,664.52), and Thomas Andrew Crockett ($989,479.34). How much insider selling is happening at KalVista Pharmaceuticals? Insiders have sold a total of 299,137 KalVista Pharmaceuticals shares in the last 24 months for a total of $3,597,127.17 sold. More Insider Trading Tools from MarketBeat Related Companies: ALIM Insider Selling BCRX Insider Selling AKRO Insider Selling RCKT Insider Selling RXRX Insider Selling ARVN Insider Selling KNSA Insider Selling IMCR Insider Selling CNTA Insider Selling EWTX Insider Selling Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: This Is the Top Large-Cap Stock Insiders Are BuyingMatador Resources Insiders Keep Buying Its Stock, Should You?Top 3 Small-Cap Stocks Insiders Are Buying Right Now3 Small Cap Stocks That Insiders Are BuyingMGM Insiders Bet Big on Its Undervalued Stock This page (NASDAQ:KALV) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding KalVista Pharmaceuticals, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALV Stock Alerts